Biodesix, Inc.

After Croatia, Czechia, Poland, and England, now also Germany is rolling out nationwide lung cancer screening in Europe - and AI is no longer optional. In Germany computer-assisted detection and volumetry are mandatory. Which means: every participating center now has to choose an AI solution. But it also raises an immediate question: which AI should you choose? Together with Noa Antonissen, Steven Schalekamp, Horst Hahn, and Colin Jacobs (loved the collaboration!), we took a structured look at what current AI products actually offer to support lung cancer screening. Our paper is now published in European Radiology (ESR Journals) 🎉 Currently there are 16 CE-marked solutions of which we mapped their capabilities to guideline-defined screening tasks. A few key observations: 🔷 Core capabilities are widely available 14/16 products support detection and measurement of solid and subsolid nodules, and 12/16 support growth assessment, forming a solid basis for screening workflows. 🔷 Strong support for common workflows, but gaps in broader coverage High task coverage is achieved for standard nodule types, while support remains limited for less common findings such as endobronchial or cystic lesions (0/16 products). 🔷 Substantial functional alignment with guidelines Many AI products cover a substantial proportion of guideline-defined tasks for EUPS and BTS, whereas products have more modest alignment with Lung-RADS v2022 and ESTI. 🔷 Evidence is growing, but still concentrated at earlier stages 60 peer-reviewed studies are available covering a total of 10 of the AI products (6 had no peer-reviewed evidence available). Only 7% of papers were prospective and none reported patient outcomes or societal impact. Back to Germany, what does this mean in practice? We are entering a phase where: - AI is mandated at the system level - but selection, validation, and integration remain local responsibilities At the same time, there is limited guidance on: - what level of evidence is sufficient - how to validate performance locally - how to organise ongoing quality assurance In my opinion, this creates both risk and inefficiency, with each hospital effectively having to build its own evaluation, procurement and governance approach. In the Netherlands, where we are preparing the implementation of AI in the breast cancer screening program, a different model was chosen: centralized, rigorous protocols for validation prior to procurement, and structured post-deployment quality control - with of course the trade-off of a longer path towards large-scale implementation. Two countries, two screening programs, both adopting AI, but with very different approaches to implementation and quality assurance. Curious to learn: what are the most important criteria you are selecting your lung cancer screening AI on? And how do you ensure quality now and over time? Full article: https://lnkd.in/emj-XWVj

Colorado’s life sciences community showed up in full force to connect, collaborate, and shape what’s next for our ecosystem at CBSA’s annual All Member Meeting + Networking event in Boulder. Thank you to our members and sponsors for turning out in record numbers! It was a standing-room-only crowd. CBSA President and CEO Elyse Blazevich kicked off the energetic afternoon, highlighting the ecosystem’s early fundraising momentum in 2026 after hitting a new high in 2025 with $3.2B raised. She emphasized Colorado’s top 20 ranking for life sciences R&D, and recognized companies choosing Colorado for their next phase of growth.  CBSA’s incoming Board of Directors Chair, Byron Hewett, highlighted the board’s vision for the Colorado Life Sciences Strategic Roadmap. This comprehensive initiative will identify our state’s strengths, pinpoint key growth opportunities, and inform priority areas for investment. He led a dynamic panel discussion providing early insights on the roadmap research and development. CBSA Board of Directors members, April Giles of End Drug Shortages Alliance and Kevin Noble of Innosphere, were joined by executives from TEConomy Partners, a leading consulting firm in innovation-driven economic development selected by CBSA to develop the strategic roadmap. TEConomy’s Ryan Helwig, Joe Simkins, and Jonathan Dworin emphasized the richness and depth of resources across Colorado’s life sciences ecosystem. Panelists and audience members shared insights on Capital + Growth, support for early-stage companies, Colorado’s exceptional talent, and opportunities to unite stakeholders as we build a comprehensive, statewide life sciences strategy. Attendees contributed to the research by participating in a live survey designed to inform roadmap development.  CBSA extends a special thanks to the St. Julien Hotel in Boulder for hosting our community and to our 2026 All Member Meeting sponsors: Bank of America, BioMed Realty, BNBuilders, Cooley LLP, Fisher Scientific, Fitzsimons Innovation Community, Higginbotham, PhRMA, SOMALOGIC LIMITED, Terumo Blood and Cell Technologies, and Umoja Biopharma, for making this event possible. #CoBioScience #StrongerTogether #Driven 

Here's the 11th article from our CEO, Scott Hutton, regarding High Performance and "self-management". Another insightful take on how to perform at your best. #biodesix #leadership #workplace #culture #engagement #BDSX